Does Time of Day For Immunotherapy Infusion Impact Efficacy

  • A randomized phase 3 trial published yesterday in “Nature Medicine,” titled Time-of-day immunochemotherapy in nonsmall cell lung cancer, evaluated whether the timing of immunochemotherapy infusions affects outcomes for patients with advanced non-small cell lung cancer (NSCLC).
  • Top oncologists at the nation’s leading academic institutions–including Dana-Farber Cancer Institute’s Dr. Paolo Tarantino, NYU Langone Perlmutter Cancer Center’s Dr. Joshua Sabari, Emory Winship Cancer Institute’s Dr. Suresh Ramalingam and the Mayo Clinic’s Dr. Vamsi Velcheti––agree the study’s findings are promising, but differ on whether they are truly practice-changing.
  • For now, with some notable exceptions, the consensus view among many oncologists with whom we spoke is extreme curiosity— rather than an immediate transformation. The data are compelling enough to warrant replication and deeper mechanistic study, but not yet definitive enough to reorganize infusion centers nationwide.

The headline from a highly respected, peer reviewed journal is irresistible. If you could simply change the time of day for your patient’s infusion of a check point inhibitor to achieve a markedly better result, why wouldn’t all practitioners immediately change their practice? A few say that is exactly what they intend to do. Many more are very interested in the results from the new study in the journal Nature, but understandably want more confirmation before they start sending all patients to morning appointments.

In conversations with SurvivorNet, academic oncologists across the country are weighing in on a newly released study investigating whether the the time of day that patients receive immunochemotherapy infusions impacts outcomes.

“This is a fascinating randomized trial,” says Dr. Joshua Sabari, an internationally claimed clinical researcher and medical oncologist who cares for lung cancer patients. “It has always been hypothesized that our immune system may be affected by our circadian rhythm, meaning that immune cells may function differently in the morning than in the late afternoon or evening. These oscillations in the function of our immune cells may affect how well immunotherapy may work in patients.”

Trial Design, Results and Reactions

In the trial, 210 patients with advanced non-small cell lung cancer received standard immunochemotherapy either before 3:00 PM (early time-of-day group) or after 3:00 PM (later time-of-day group). Median progression-free survival was 11.3 months in the early group versus 5.7 months in the later group — translating to roughly a 50% reduction in the risk of disease progression with earlier treatment.

The authors tie these differences to circadian biology: immune cell activity, particularly CD8⁺ T-cell subsets, appears modulated by time-of-day, potentially enhancing anti-tumor effects when therapies are given earlier.

Reactions to the trial from leading oncologists have been mixed.

“There are those that just feel this is the final confirmation we should give immunotherapy only in the morning before 3:00 PM and those who instead advise caution and say we should first confirm it in additional trials before jumping to changing practice,” says Dr. Paolo Tarantino, a leading clinical researcher and breast oncologist serving as a Research Fellow in Medicine at Harvard Medical School.

Early Excitement Around The Data

For some experts, the implications are striking.

“The results are provocative and substantiate findings from other retrospective reports that administration of immunotherapy during the earlier part of the day is associated with more favorable outcomes,” says Dr. Suresh Ramalingam, a thoracic oncologist who serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. “From a practical standpoint, this should be easy to implement in the clinic.” However, he also added that time of day matters less for subsequent cycles of therapy (after the first one) given the long half-life of PD-1 inhibitors.

Dr. Vamsi Velcheti, Chair of the Division of Hematology & Oncology at the Mayo Clinic Comprehensive Cancer Center in Jacksonville, adds, “What stands out most is that a simple, non-pharmacologic factor — the time of day treatment is delivered — was associated with meaningful improvements in progression-free and overall survival in a randomized trial, supported by immune correlates suggesting enhanced T-cell activity earlier in the day.”

Speaking to the potential to optimize treatment delivery without altering therapy, Dr. Velcheti says, “Personally, this is both striking and exciting, because it points to a biologically plausible way to optimize outcomes without changing the drugs themselves.”

Caution In Interpreting The Findings

However, experts also caution that despite compelling signals, the findings are not yet sufficient to change standard practice broadly — highlighting the need for replication in diverse populations, mechanistic validation, and assessment across other tumor types before guidelines shift.

“It sparked a lot of discussion for many reasons,” says Dr. Paolo Tarantino. “But, there was a lot of skepticism because these drugs have a very long half-life. Real world data can be heavily influenced by confounding factor biases.”

Because the study population was limited to centers in China and mechanisms linking timing to clinical benefit remain to be fully defined, experts urge larger multi-institutional studies before adopting time-of-day scheduling as a new standard. “We should confirm these studies to ensure that the data are applicable in a broader group of patients outside China,” Dr. Ramalingam says.

Echoing that need for scientific caution and deeper mechanistic insight, Dr. Sabari emphasizes that the biological underpinnings still require clarification. “Further studies are needed to better understand the biological ramifications of these findings,” says Dr. Sabari.

Nonetheless, Dr. Tarantino emphasizes that biological implications don’t always have to be clearly understood for clinicians to change practice, saying, “If we see an effect on a randomized phase three trial, we do that irrespective of what is the reason. Just because it’s more important to see the actual consequences of the actions rather than thinking of why.”

A Signal Worth Watching

“I think we now have enough data at least to be curious — to understand that it may have an impact,” says Dr. Tarantino. “But the truth is that there are several other things. Let’s say, for instance, diet, the microbiome, psychological factors — so many other things have been studied in the context of immunotherapy that suggest they may be relevant, but it’s not that we really implement them in any way.”

Tarantino’s point reflects a broader tension in oncology: biologically plausible signals often emerge long before they translate into standardized clinical recommendations. The immune system is complex and influenced by multiple environmental and physiologic variables — from circadian rhythm to gut flora composition to stress hormones. While each has been linked in some way to immunotherapy response, few have crossed the evidentiary threshold required to alter infusion schedules or patient counseling in routine practice.

“We don’t tell our patients receiving immunotherapy to adopt a specific diet to manipulate their microbiome or to undergo psychological interventions solely because of immunotherapy,” Dr. Tarantino notes. In that sense, time-of-day treatment joins a growing list of intriguing but not yet operationalized modifiers of response.

For now, with some notable exceptions, the consensus view among many oncologists with whom we spoke is extreme curiosity— rather than an immediate transformation. The data are compelling enough to warrant replication and deeper mechanistic study, but not yet definitive enough to reorganize infusion centers nationwide.